These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29213335)

  • 1. Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats.
    Li J; Liu X; Fang Q; Ding M; Li C
    Diabetol Metab Syndr; 2017; 9():94. PubMed ID: 29213335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of liraglutide on endoplasmic reticulum stress in the renal tissue of type 2 diabetic rats.
    Zhao XY; Yu TT; Liu S; Liu YJ; Liu JJ; Qin J
    World J Diabetes; 2020 Dec; 11(12):611-621. PubMed ID: 33384768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide improves pancreatic islet β cell apoptosis in rats with type 2 diabetes mellitus by inhibiting the IKKε/NF-κB pathway.
    Liu YT; He T; Li HQ; Jiang P
    Eur Rev Med Pharmacol Sci; 2021 Jul; 25(14):4818-4828. PubMed ID: 34337733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Effects and Mechanism of Liraglutide in Rats with Type 2 Diabetes and Metabolic-associated Fatty Liver Disease.
    Zhao X; Liu Y; Liu J; Qin J
    Endocr Metab Immune Disord Drug Targets; 2022; 22(9):963-969. PubMed ID: 35081898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model.
    Wihastuti TA; Heriansyah T; Hanifa H; Andarini S; Sholichah Z; Sulfia YH; Adam AA; Refialdinata J; Lutfiana NC
    Endocr Regul; 2018 Apr; 52(2):69-75. PubMed ID: 29715185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic insights into the effects of quercetin and/or GLP-1 analogue liraglutide on high-fat diet/streptozotocin-induced type 2 diabetes in rats.
    Gaballah HH; Zakaria SS; Mwafy SE; Tahoon NM; Ebeid AM
    Biomed Pharmacother; 2017 Aug; 92():331-339. PubMed ID: 28554128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta-cell apoptosis via mediating the ASK1/JNK/BAX pathway in rats with type 2 diabetes.
    Wang W; Wu RD; Chen P; Xu XJ; Shi XZ; Huang LH; Shao ZL; Guo W
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3212. PubMed ID: 31411368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver paraoxonase 3 expression and the effect of liraglutide treatment in a rat model of diabetes.
    Liu Y; Zhu D; Dong G; Zeng Y; Jiang P; Xiao Y
    Adv Clin Exp Med; 2021 Feb; 30(2):157-163. PubMed ID: 33650330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis.
    Su K; Yi B; Yao BQ; Xia T; Yang YF; Zhang ZH; Chen C
    Pharmacol Res; 2020 Jun; 156():104778. PubMed ID: 32247822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide protects from renal damage via Akt-mTOR pathway in rats with diabetic kidney disease.
    Liao TT; Zhao LB; Liu H; He RL; Wang YQ; Li J
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):117-125. PubMed ID: 31389583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats.
    Xu X; Wang W; Lin L; Chen P
    Tissue Cell; 2020 Oct; 66():101382. PubMed ID: 32933722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamine up-regulates pancreatic sodium-dependent neutral aminoacid transporter-2 and mitigates islets apoptosis in diabetic rats.
    Medras ZJH; El-Sayed NM; Zaitone SA; Toraih EA; Sami MM; Moustafa YM
    Pharmacol Rep; 2018 Apr; 70(2):233-242. PubMed ID: 29475006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-α pathway.
    Ji Y; Zhao Z; Cai T; Yang P; Cheng M
    Mol Med Rep; 2014 Apr; 9(4):1254-8. PubMed ID: 24535553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of Tongxinluo and Simvastatin on the stabilization of vulnerable atherosclerotic plaques of aorta in aortic atherosclerosis and molecular mechanism thereof: a comparative study with rabbits].
    Li Z; Yang YJ; Qin XW; Ruan YM; Chen X; Meng L; Zhang HD
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3146-50. PubMed ID: 17313769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
    Zhao XY; Zhang LL; Suolang QZ; Yang GY; Li L; Li SB; Chen WW
    Zhonghua Gan Zang Bing Za Zhi; 2014 Nov; 22(11):849-53. PubMed ID: 25531383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide alters DPP4 in the circumvallate papillae of type 2 diabetic rats.
    Cao X; Zhou X; Liu XM; Zhou LH
    J Mol Endocrinol; 2016 Jul; 57(1):13-21. PubMed ID: 27151572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gycyrrhizic acid alleviates atherosclerotic lesions in rats with diabetes mellitus.
    Zhao Y; Li W; Zhang D
    Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34476498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chitosan-stabilized selenium nanoparticles alleviate cardio-hepatic damage in type 2 diabetes mellitus model via regulation of caspase, Bax/Bcl-2, and Fas/FasL-pathway.
    Mohamed AA; Khater SI; Hamed Arisha A; Metwally MMM; Mostafa-Hedeab G; El-Shetry ES
    Gene; 2021 Feb; 768():145288. PubMed ID: 33181259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of liraglutide against ER stress in the liver of high-fat diet-induced insulin-resistant rats.
    Yang J; Ao N; Du J; Wang X; He Y
    Endocrine; 2015 May; 49(1):106-18. PubMed ID: 25471281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
    Bruen R; Curley S; Kajani S; Lynch G; O'Reilly ME; Dillon ET; Brennan EP; Barry M; Sheehan S; McGillicuddy FC; Belton O
    J Pharmacol Exp Ther; 2019 Sep; 370(3):447-458. PubMed ID: 31270216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.